These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 9267826)
1. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826 [TBL] [Abstract][Full Text] [Related]
2. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656 [TBL] [Abstract][Full Text] [Related]
3. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605 [TBL] [Abstract][Full Text] [Related]
4. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675 [TBL] [Abstract][Full Text] [Related]
5. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters. Cianciulli AM; Guadagni F; Marzano R; Benevolo M; Merola R; Giannarelli D; Marandino F; Vocaturo G; Mariani L; Mottolese M J Exp Clin Cancer Res; 2003 Jun; 22(2):265-71. PubMed ID: 12866577 [TBL] [Abstract][Full Text] [Related]
6. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965 [TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression. Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167 [TBL] [Abstract][Full Text] [Related]
9. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175 [TBL] [Abstract][Full Text] [Related]
10. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898 [TBL] [Abstract][Full Text] [Related]
11. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray. Giltnane JM; Murren JR; Rimm DL; King BL Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393 [TBL] [Abstract][Full Text] [Related]
12. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926 [TBL] [Abstract][Full Text] [Related]
13. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. Persons DL; Bui MM; Lowery MC; Mark HF; Yung JF; Birkmeier JM; Wong EY; Yang SJ; Masood S Ann Clin Lab Sci; 2000 Jan; 30(1):41-8. PubMed ID: 10678582 [TBL] [Abstract][Full Text] [Related]
14. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Persons DL; Borelli KA; Hsu PH Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184 [TBL] [Abstract][Full Text] [Related]
15. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Coogan CL; Estrada CR; Kapur S; Bloom KJ Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912 [TBL] [Abstract][Full Text] [Related]
16. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540 [TBL] [Abstract][Full Text] [Related]
17. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506 [TBL] [Abstract][Full Text] [Related]
18. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. Liu W; Zhong S; Chen J; Yu Y J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554 [TBL] [Abstract][Full Text] [Related]
19. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036 [TBL] [Abstract][Full Text] [Related]